A detailed history of Bank Of America Corp transactions in Citius Pharmaceuticals, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 28,930 shares of CTXR stock, worth $74,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,930
Previous 159,422 81.85%
Holding current value
$74,928
Previous $92,000 84.78%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.48 - $1.02 $62,636 - $133,101
-130,492 Reduced 81.85%
28,930 $14,000
Q2 2024

Aug 14, 2024

BUY
$0.58 - $1.03 $62,191 - $110,443
107,227 Added 205.44%
159,422 $92,000
Q1 2024

May 15, 2024

SELL
$0.6 - $0.9 $77,052 - $115,578
-128,421 Reduced 71.1%
52,195 $46,000
Q4 2023

Feb 14, 2024

BUY
$0.65 - $0.86 $36,600 - $48,424
56,308 Added 45.3%
180,616 $137,000
Q2 2023

Aug 14, 2023

BUY
$1.08 - $1.65 $134,231 - $205,075
124,288 Added 621440.0%
124,308 $149,000
Q1 2023

May 12, 2023

SELL
$0.78 - $1.42 $105 - $191
-135 Reduced 87.1%
20 $0
Q4 2022

Feb 10, 2023

BUY
$0.79 - $1.28 $120 - $195
153 Added 7650.0%
155 $0
Q3 2022

Nov 14, 2022

SELL
$0.14 - $1.33 $7 - $69
-52 Reduced 96.3%
2 $0
Q2 2022

Aug 12, 2022

SELL
$0.88 - $1.87 $15,806 - $33,588
-17,962 Reduced 99.7%
54 $0
Q1 2022

May 16, 2022

SELL
$1.38 - $1.89 $120,916 - $165,603
-87,621 Reduced 82.95%
18,016 $32,000
Q4 2021

Feb 08, 2022

BUY
$1.51 - $2.2 $93,846 - $136,730
62,150 Added 142.92%
105,637 $162,000
Q3 2021

Nov 15, 2021

BUY
$1.74 - $2.6 $12,046 - $17,999
6,923 Added 18.93%
43,487 $88,000
Q2 2021

Sep 13, 2021

BUY
$1.51 - $4.23 $55,211 - $154,665
36,564 New
36,564 $127,000

Others Institutions Holding CTXR

About Citius Pharmaceuticals, Inc.


  • Ticker CTXR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 146,130,000
  • Market Cap $378M
  • Description
  • Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic l...
More about CTXR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.